10001 Results for "

full-length

" in MedChemExpress (MCE) Product Catalog:
Products (10001)

10001 Results for "full-length" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-RI00500
Target:  

MicroRNA

Research Areas:  

Cancer

hsa-miR-27b-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-121879
CAS No.: 1957276-35-5
Purity:  99.39%
Target:  

SHP2 Phosphatase

Research Areas:  

Cancer

SHP836 is a SHP2 allosteric inhibitor, with an IC50 of 12 μM for the full length SHP2 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-Q51222
CAS No.: 100264-64-0
Research Areas:  

Cancer

ZINC110492 is a selective ligand of CS-ΔEx4 (a splicing isoform of citrate synthase (CS)). ZINC110492 does not bind to CS full-length (CS-FL). ZINC110492 inhibits colorectal cancer (CRC) cell growth in cells overexpressing CS-ΔEx4 with an IC50 of 7.840 µM. ZINC110492 significantly decreases both citrate and 2-hydroxyglutarate (2-HG) levels in the CS-ΔEx4-overexpressing SW1116 cells .
loading...
    loading...
Cat. No.: HY-P4808
CAS No.: 329897-62-3
Target:  

Amyloid-β Autophagy

Research Areas:  

Neurological Disease

PHF6 (VQIVYK) is a self-assembly sequence capable of initiating the full-length tau protein aggregation and is mapped to the third microtubule-binding repeat region of the tau protein .
loading...
    loading...
Cat. No.: HY-116501
CAS No.: 1621375-32-3
Purity:  99.51%
Target:  

Androgen Receptor

Research Areas:  

Cancer

VPC-14449 is a potent and selective inhibitor of the DNA-binding domain of the androgen receptor (AR-DBD), with IC50 of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostate cancer .
loading...
    loading...
Cat. No.: HY-18713
CAS No.: 1438881-19-6
Target:  

PKC ROCK

CRT0066854 is a potent and selective atypical PKC isoenzymes inhibitor. CRT0066854 is against full-length (FL) PKCι, PKCζ, and ROCK-II kinases with IC50 values of 132 nM, 639 nM, and 620 nM, respectively .
loading...
    loading...
Cat. No.: HY-18713A
CAS No.: 2250019-91-9
Target:  

PKC ROCK

Research Areas:  

Neurological Disease

CRT0066854 hydrochloride is a potent and selective atypical PKCs inhibitor. CRT0066854 is against full-length (FL) PKCι, PKCζ, and ROCK-II kinases with IC50 values of 132 nM, 639 nM, and 620 nM, respectively .
loading...
    loading...
Cat. No.: HY-19738
CAS No.: 185351-19-3
Target:  

Tau Protein

Research Areas:  

Neurological Disease

NQTrp, an aromatic naphthoquinone-tryptophan hybrid molecule, an inhibitor of the aggregation of the tau protein with generic anti-amyloidogenic effects. NQTrp inhibits the in vitro aggregation of hexapeptide ( 41GCWMLY 46 within the N-terminus of γD-crystallin) as well as full-length γD-crystallin .
loading...
    loading...
Cat. No.: HY-138643
CAS No.: 185351-23-9
Purity:  99.97%
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Cl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein .
loading...
    loading...
Cat. No.: HY-P4808A
Target:  

Amyloid-β Autophagy

Research Areas:  

Neurological Disease

PHF6 (VQIVYK) TFA is a self-assembly sequence capable of initiating the full-length tau protein aggregation. PHF6 TFA is mapped to the third microtubule-binding repeat region of the tau protein .
loading...
    loading...
Cat. No.: HY-P990654
CAS No.: 1253180-81-2

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology

Radretumab is a protein that blocks myostatin that targets Fibronectin. Radretumab is a full-length Human IgG1 antibody.
loading...
    loading...
Cat. No.: HY-RI00144
Target:  

MicroRNA

Research Areas:  

Cancer

hsa-miR-1246 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
loading...
    loading...
Cat. No.: HY-RI00212
Target:  

MicroRNA

Research Areas:  

Cancer

hsa-miR-1290 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
loading...
    loading...
Cat. No.: HY-RI00057
Target:  

MicroRNA

Research Areas:  

Cancer

hsa-miR-107 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
loading...
    loading...
Cat. No.: HY-154438
CAS No.: 4155-82-2
Purity:  ≥98.0%
RDR 02308 is a TLR4-MyD88 binding inhibitor that inhibits full-length β-lactamase .
loading...
    loading...
Cat. No.: HY-P10635
CAS No.: 403668-80-4
Research Areas:  

Inflammation/Immunology

TKD (450-463) is a 14-mer peptide (TKDNNLLGRFELSG). TKD (450-463) is able to stimulate the cytolytic and proliferative activity of NK cells at concentrations equivalent to full-length Hsp70 protein .
loading...
    loading...
Cat. No.: HY-178683
CAS No.: 2438125-72-3
Target:  

BCL6

Research Areas:  

Cancer

ALV-05-077-01 is a BCL6/BCL6B degrader. ALV-05-077-01 binds to CRBN and recruits specific zinc finger proteins as neo-substrates for ubiquitination and proteasomal degradation. ALV-05-077-01 induces the degradation of full-length endogenous BCL6 zinc finger protein. ALV-05-077-01 induces the degradation of full-length endogenous BCL6B zinc finger protein. ALV-05-077-01 can be used in the research of hematological malignancies .
loading...
    loading...
Cat. No.: HY-170553
Target:  

α-synuclein

Research Areas:  

Neurological Disease

ZPD-2 inhibits the aggregation of C-terminally truncated and full-length α-synuclein. ZPD-2 inhibits the formation and fibrillation of α-Syn, thereby preventing its propagation. ZPD-2 can be used in research of Parkinson's disease .
loading...
    loading...
Cat. No.: HY-123359
CAS No.: 414909-09-4
Research Areas:  

Others

RTC14 is a read-through compound (RTC) that can induce ribosomes to bypass nonsense mutations in mRNA and allow the production of full-length functional proteins. RTC14 has the potential to be used in the research of various genetic disorders, such as nonsense mutations in the ataxia-telangiectasia mutated (ATM) gene and the dystrophin gene .
loading...
    loading...
Cat. No.: HY-RI00161
Target:  

MicroRNA

Research Areas:  

Cancer

hsa-miR-1257 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
loading...
    loading...